Development of an efficient and selective radioligand for bradykinin B 1 receptor occupancy studies

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 24, 2004, Pages 6045-6048

  Su, Dai Shi ^a   Markowitz, M Kristine ^a   Murphy, Kathy L ^a   Wan, Bang Lin ^a   Zrada, Matthew M ^a   Harrell, C Meacham ^a   O'Malley, Stacy S ^a   Hess, J Fred ^a   Ransom, Rick W ^a   Chang, Ray S ^a   Wallace, Michael A ^a   Raab, Conrad E ^a   Dean, Dennis C ^a   Pettibone, Douglas J ^a   Freidinger, Roger M ^a   Bock, Mark G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonist; Bradykinin B 1 receptor; Ex vivo; Radioligand

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; DIHYDROQUINOLINE DERIVATIVE; RADIOLIGAND; SULFUR 35;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; GENE OVEREXPRESSION; NONHUMAN; RAT; RECEPTOR OCCUPANCY; TRANSGENE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BINDING, COMPETITIVE; HUMANS; ISOTOPE LABELING; LIGANDS; QUINOXALINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, BRADYKININ B1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR RADIOISOTOPES;

EID: 8844253298     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.074     Document Type: Article

References (23)

1. F. Marceau, and D. Regoli Nat. Rev. Drug Discov. 3 10 2004 845 852
2. M.G. Bock, J.F. Hess, and D.J. Pettibone A.M. Doherty Annual Reports in Medicinal Chemistry 38 2003 Elsevier USA 111 120
3. R. Couture, M. Harrisson, R.M. Vianna, and F. Cloutier Eur. J. Pharmacol. 429 2001 161 176
4. M.G. Bock, and J. Longmore Bradykinin antagonists: new opportunities Curr. Opin. Chem. Biol. 4 2000 401 406
5. F. Marceau Kinin Immunopharmacology 30 1995 1 26
6. D. Regoli, and J. Barabe Pharmacol. Rev. 32 1980 1 46
7. N.M.J. Rupniak, J. Longmore, and R.G. Hill J. Wood Molecular Basis of Pain Induction 2000 John Wiley pp 149-174
8. J.B. Pesquero, R.C. Araujo, P.A. Heppenstall, C.L. Stucky, J.A. Silva Jr., T. Walther, S.M. Oliveira, J.L. Pesquero, A.C.M. Paiva, J.B. Calixto, G.R. Lewin, and M. Bader Proc. Natl. Acad. Sci. U.S.A 97 2000 8140 8145
9. J. Ferreira, M.M. Campos, R. Araujo, M. Bader, J.B. Pesquero, and J.B. Calixto Neuropharmacology 43 2002 1188 1197
10. G.R. Seabrook, B.J. Bowery, R. Heavens, N. Brown, H. Ford, D.J.S. Sirinathsinghi, J.A. Borkowski, J.F. Hess, C.D. Strader, and R.G. Hill Neuropharmacology 36 1997 1009 1017
11. Q.-P. Ma, R.G. Hill, and D.J.S. Sirinathsinghi Neuroreport 11 2000 4003 4005
12. G. Wotherspoon, and J. Winter Neurosci. Lett. 294 2000 175 178
13. D.-S. Su, M.K. Markowitz, R.M. DiPardo, K.L. Murphy, C.M. Harrell, S.S. O'Malley, R.W. Ransom, R.S.L. Chang, S. Ha, F.J. Hess, D.J. Pettibone, G.S. Mason, S. Boyce, R.M. Freidinger, and M.G. Bock J. Am. Chem. Soc. 125 2003 7516 7517
14. M.R. Wood, J.J. Kim, W. Han, B.D. Dorsey, C.F. Homnick, R.M. DiPardo, S.D. Kuduk, T. MacNeil, K.L. Murphy, E.V. Lis, R.W. Ransom, G.L. Stump, J.J. Lynch, S.S. O'Malley, P.J. Miller, T.-B. Chen, C.M. Harrell, R.S.L. Chang, S. Punam, J.D. Ellis, P.J. Bondiskey, D.J. Pettibone, R.M. Freidinger, and M.G. Bock J. Med. Chem. 46 2003 1803 1806
15. 35S] into the requisite starting material were unavailable
16. For the assay protocol, see Ref.5a
17. 35S (∼87 days)
18. Panlabs (MDS Pharma Services, Bothell, WA)
19. R.W. Ransom, C.M. Harrell, D.R. Reiss, K.L. Murphy, R.S.-L. Chang, J.F. Hess, P.J. Miller, S.S. O'Malley, P.J. Hey, P. Kunapuli, D.-S. Su, M.K. Markowitz, M.A. Wallace, A.N. Jones, D.C. Dean, D.J. Pettibone, R.M. Freidinger, and M.G. Bock Eur. J. Pharmacol. 499 2004 77 84
20. T. MacNeil, S. Feighner, D.L. Hreniuk, J.F. Hess, and L.H. Van der Ploeg Can. J. Physiol. Pharmacol. 75 1997 735 740
21. 1 Ki: 0.02 nM (human), 0.05 nM (rabbit), 0.5 nM (dog), 34.0 nM (rat), and 0.02 (rhesus monkey)
22. J.F. Hess, R.W. Ransom, Z. Zeng, R.S.L. Chang, P.J. Hey, L. Warren, C.M. Harrell, K.L. Murphy, T.-B. Chen, P.J. Miller, E. Lis, D. Reiss, R.E. Gibson, M.K. Markowitz, R.M. Dipardo, D.-S. Su, M.G. Bock, R.J. Gould, and D.J. Pettibone J. Pharmacol. Exp. Therapeut. 310 2 2004 488 497
23. 1 receptor but relatively low specific activity (75 Ci/μmol), were also tested in the same assay format. Both required long incubation times (leading to dissociation artifacts) and high tissue concentrations (association artifacts) and could not be used for the development of a reliable assay